Shares of Zotefoams plc (LON:ZTF) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $343.87 and traded as high as $449.00. Zotefoams shares last traded at $449.00, with a volume of 4,736 shares changing hands.

The company’s fifty day moving average price is GBX 442.67 and its 200-day moving average price is GBX 343.87. The stock has a market capitalization of $218.80 million and a PE ratio of 35.08. The company has a quick ratio of 0.86, a current ratio of 1.47 and a debt-to-equity ratio of 52.70.

Zotefoams (LON:ZTF) last released its earnings results on Tuesday, August 11th. The company reported GBX 4.48 ($0.06) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Zotefoams plc will post 1790.000063 earnings per share for the current year.

The firm also recently announced a dividend, which was paid on Friday, October 9th. Stockholders of record on Thursday, September 10th were issued a dividend of GBX 2.03 ($0.03) per share. The ex-dividend date was Thursday, September 10th. This represents a dividend yield of 0.47%. Zotefoams’s payout ratio is 31.25%.

In related news, insider David Stirling sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of GBX 404 ($5.28), for a total transaction of £222,200 ($290,305.72).

About Zotefoams (LON:ZTF)

Zotefoams plc, together with its subsidiaries, manufactures, distributes, and sells polymer foam in the United Kingdom and Eire, Continental Europe, North America, and internationally. The company operates through Polyolefins, High-Performance Products (HPP), and MuCell Extrusion LLC (MEL) segments. It offers AZOTE family of polyolefin foams under the Plastazote, Evazote, and Supazote brands; and ZOTEK range of high-performance foams manufactured from fluoropolymers, engineering polymers, and specialty elastomers under the ZOTEK F, ZOTEK N, and ZOTEK PEBA brand names.

Featured Story: Overbought

Receive News & Ratings for Zotefoams Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zotefoams and related companies with's FREE daily email newsletter.